The therapeutic potential of CAIX-targeted RLT in ccRCC, either as monotherapy or in combination with TKIs or immunotherapy, remains to be determined in larger, late-phase trials. This evidence concerns the gene CA9 and nonpapillary renal cell carcinoma.